Search Results - "Chow, L. Q. M."

A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer by Chow, L. Q. M., Blais, N., Jonker, D. J., Laurie, S. A., Diab, S. G., Canil, C., McWilliam, M., Thall, A., Ruiz-Garcia, A., Zhang, K., Tye, L., Chao, R. C., Camidge, D. R.

“…Purpose The primary objective of this phase I dose-escalation study was to identify the maximum tolerated dose (MTD) of sunitinib plus pemetrexed in patients…”
Get full text

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases by Vokes, E.E., Ready, N., Felip, E., Horn, L., Burgio, M.A., Antonia, S.J., Arén Frontera, O., Gettinger, S., Holgado, E., Spigel, D., Waterhouse, D., Domine, M., Garassino, M., Chow, L.Q.M., Blumenschein, G., Barlesi, F., Coudert, B., Gainor, J., Arrieta, O., Brahmer, J., Butts, C., Steins, M., Geese, W.J., Li, A., Healey, D., Crinò, L.

“…Long-term data with immune checkpoint inhibitors in non-small-cell lung cancer (NSCLC) are limited. Two phase III trials demonstrated improved overall survival…”
Get full text

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors by Hellmann, M.D., Kim, T.-W., Lee, C.B., Goh, B.-C., Miller, W.H., Oh, D.-Y., Jamal, R., Chee, C.-E., Chow, L.Q.M., Gainor, J.F., Desai, J., Solomon, B.J., Das Thakur, M., Pitcher, B., Foster, P., Hernandez, G., Wongchenko, M.J., Cha, E., Bang, Y.-J., Siu, L.L., Bendell, J.

“…Preclinical evidence suggests that MEK inhibition promotes accumulation and survival of intratumoral tumor-specific T cells and can synergize with immune…”
Get full text

Genetic landscape of patients with ALK-rearranged non–small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study by Tan, D.S-W., Thomas, M., Kim, D-W., Szpakowski, S., Urban, P., Mehra, R., Chow, L.Q.M., Sharma, S., Solomon, B.J., Felip, E., Camidge, D.R., Vansteenkiste, J., Petruzzelli, L., Pantano, S., Shaw, A.T.

“…•We explored the role of NGS in improving our understanding of response to ceritinib.•Genomic profiles of ALK inhibitor resistance are diverse.•The driver…”
Get full text

Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience by CHOW, L. Q. M, BAHLIS, N, RUSSELL, J, CHAUDHRY, A, MORRIS, D, BROWN, C, STEWART, D. A

“…Recent reports from large amyloidosis referral centers suggest that primary systemic AL amyloidosis patients treated with high-dose melphalan (HDM) and…”
Get full text

Лечение токсических побочных эффектов у пациентов с распространенным медуллярным раком щитовидной железы by Brose, M. S., Bible, K. C., Chow, L. Q. M., Gilbert, J., Grande, C., Worden, F., Haddad, R.

“…Большой прогресс в лечении распространенного медуллярного рака щитовидной железы за последние 5 лет достигнут благодаря одобрению 2 препаратов – вандетаниба и…”
Get full text

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors by Hellmann, M D, Kim, T-W, Lee, C B, Goh, B-C, Miller, Jr, W H, Oh, D-Y, Jamal, R, Chee, C-E, Chow, L Q M, Gainor, J F, Desai, J, Solomon, B J, Das Thakur, M, Pitcher, B, Foster, P, Hernandez, G, Wongchenko, M J, Cha, E, Bang, Y-J, Siu, L L, Bendell, J

“…Preclinical evidence suggests that MEK inhibition promotes accumulation and survival of intratumoral tumor-specific T cells and can synergize with immune…”
Get full text

BM-32 CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL by Shaw, A., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Ross Camidge, D., Vansteenkiste, J., Sharma, S., De Pas, T., Riely, G. J., Solomon, B. J., Wolf, J., Thomas, M., Schuler, M., Liu, G., Santoro, A., Geraldes, M., Sen, P., Boral, A. J., Yovine, A., Kim, D.-W.

“…BACKGROUND: Ceritinib is an ALK inhibitor (ALKi) recently approved for patients with ALK+ advanced NSCLC. Efficacy and safety were evaluated in a subset of…”
Get full text